Helixmith Co., Ltd.

This early-phase trial tested the safety of a gene therapy called Engensis (VM202) in 12 adults with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder that causes muscle weakness. Participants received multiple injections into their leg muscles and were monito…

This study looked at the long-term safety of an experimental drug called Engensis for people with ALS (Lou Gehrig's disease). Eight people who had already received Engensis in an earlier study were followed for 6 more months. Researchers tracked side effects to see if the drug re…

This study tested a gene therapy called VM202 (Engensis) in 52 people with critical limb ischemia, a severe form of leg artery disease that causes pain and can lead to amputation. Participants received either low-dose, high-dose, or placebo injections into their calf muscles. The…

This early-stage study tested the safety of a gene therapy called VM202 in 12 people with critical limb ischemia, a severe form of leg artery disease causing pain and ulcers. Participants received injections into their leg muscles and were monitored for side effects and pain reli…

This early-phase trial tested a gene therapy called VM202RY in 9 people with ischemic heart disease who had incomplete revascularization after bypass surgery. The therapy was injected directly into heart muscle areas that still had poor blood flow. The main goal was to check safe…

This study followed 101 people who had previously received either the experimental drug Engensis or a placebo for painful diabetic neuropathy. No new treatment was given; researchers simply monitored participants for 6 months to see if any safety issues or lasting pain relief app…

This Phase 3 study tested whether injections of engensis, a gene therapy, can reduce pain in the feet and legs caused by diabetic nerve damage. 162 adults with type 1 or 2 diabetes received either engensis or a placebo. The main goal was to see if pain scores improved over 180 da…

This study tested whether a gene therapy called VM202 could safely reduce pain in people with diabetic peripheral neuropathy. Over 500 adults with type 1 or type 2 diabetes received either VM202 injections or a placebo in their legs. The main goal was to see if the treatment lowe…

This study tested whether a gene therapy called engensis can safely reduce pain from diabetic nerve damage over 6 to 12 months. About 100 people who completed an earlier trial received either engensis or placebo injections into their leg muscles. Researchers measured changes in d…

This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS). Participants received either engensis or a placebo injection into their muscles. The main goal was to check for side effects, while also exploring effects o…

This early-phase trial tested a gene therapy called Engensis (VM202) in 12 people with painful diabetic peripheral neuropathy. Participants received injections into their calf muscles to see if it was safe and could reduce pain. The study focused on safety and pain scores over 12…

This study tested a gene therapy called Engensis (VM202) to see if it safely reduces pain in people with diabetic peripheral neuropathy. 104 adults with type 1 or 2 diabetes and leg pain for at least 6 months received either low-dose, high-dose, or placebo injections into their c…

This early-phase trial tested whether a gene therapy called VM202 is safe when injected into muscles of 18 people with ALS. The study focused on side effects over 9 months, not on whether the treatment improves symptoms. All participants had ALS for less than 2 years and had at l…